Galmed Pharmaceuticals Ltd (GLMD) Expected to Announce Earnings of -$0.22 Per Share
Brokerages expect Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to post ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Galmed Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.17). Galmed Pharmaceuticals posted earnings of ($0.17) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.4%. The company is expected to announce its next earnings results on Wednesday, May 8th.
On average, analysts expect that Galmed Pharmaceuticals will report full-year earnings of ($1.30) per share for the current financial year, with EPS estimates ranging from ($1.74) to ($0.72). For the next year, analysts forecast that the company will report earnings of ($1.68) per share, with EPS estimates ranging from ($2.02) to ($1.34). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Galmed Pharmaceuticals had a negative return on equity of 18.55% and a negative net margin of 423.62%.
Shares of NASDAQ GLMD traded down $0.29 during midday trading on Thursday, hitting $8.15. The company’s stock had a trading volume of 189,736 shares, compared to its average volume of 114,986. Galmed Pharmaceuticals has a 12-month low of $4.84 and a 12-month high of $27.06. The company has a market cap of $129.67 million, a price-to-earnings ratio of -8.32 and a beta of 2.68.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Galmed Pharmaceuticals during the 4th quarter worth $33,000. Northern Trust Corp boosted its position in Galmed Pharmaceuticals by 16.3% during the 4th quarter. Northern Trust Corp now owns 12,215 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,715 shares in the last quarter. Trellus Management Company LLC bought a new stake in Galmed Pharmaceuticals during the 3rd quarter valued at $227,000. Wells Fargo & Company MN bought a new stake in Galmed Pharmaceuticals during the 3rd quarter valued at $297,000. Finally, ETF Managers Group LLC boosted its position in Galmed Pharmaceuticals by 48.9% during the 4th quarter. ETF Managers Group LLC now owns 34,656 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 11,382 shares in the last quarter. Institutional investors own 48.10% of the company’s stock.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Read More: QQQ ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.